Research output per year
Research output per year
Personal profile
Research interests
Non-Hodgkin's and Hodgkin's lymphoma, chronic lymphocytic leukemia, hematologic malignancies
Clinical interests
Non-Hodgkin's and Hodgkin's lymphoma, chronic lymphocytic leukemia, hematologic malignancies
Fingerprint
Dive into the research topics where Nancy Bartlett is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma
Merryman, R. W., Redd, R. A., Freedman, A. S., Ahn, I. E., Brown, J. R., Crombie, J. L., Davids, M. S., Fisher, D. C., Jacobsen, E. D., Kim, A. I., LaCasce, A. S., Ng, S., Odejide, O. O., Parry, E. M., Isufi, I., Kline, J., Cohen, J. B., Mehta-Shah, N., Bartlett, N. L. & Mei, M. & 5 others, , Jan 2024, In: Annals of Hematology. 103, 1, p. 185-198 14 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma
Fehniger, T. A., Watkins, M. P., Ezenwajiaku, N., Wan, F., Hurd, D. D., Cashen, A. F., Blum, K. A., Goy, A., Fenske, T. S., Wagner-Johnston, N. D., Carson, K., Siegel, M. J., Russler-Germain, D., Schneider, S. E., Mehta-Shah, N., Kahl, B. & Bartlett, N. L., Mar 2024, In: Haematologica. 109, 3, p. 953-957 5 p.Research output: Contribution to journal › Letter › peer-review
Open Access -
Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma
Ghobadi, A., Foley, N. C., Cohen, J., Rettig, M. P., Cashen, A. F., Gehrs, L., Christ, S., Street, E., Wallace, N., Ritchey, J., Mehta-Shah, N., Westervelt, P., Fehniger, T. A., Kahl, B., Bartlett, N. L. & DiPersio, J. F., Feb 13 2024, In: Blood Advances. 8, 3, p. 513-522 10 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1
Crosswell, H. E., LaCasce, A. S., Bartlett, N. L., Straus, D. J., Savage, K. J., Zinzani, P. L., Collins, G. P., Fanale, M., Fenton, K., Dong, C., Miao, H. & Grigg, A. P., Mar 2024, In: Haematologica. 109, 3, p. 982 1 p.Research output: Contribution to journal › Letter › peer-review
Open Access -
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Crombie, J. L., Graff, T., Falchi, L., Karimi, Y. H., Bannerji, R., Nastoupil, L., Thieblemont, C., Ursu, R., Bartlett, N., Nachar, V., Weiss, J., Osterson, J., Patel, K., Brody, J., Abramson, J. S., Lunning, M., Shah, N. N., Ayed, A., Kamdar, M. & Parsons, B. & 13 others, , Apr 18 2024, In: Blood. 143, 16, p. 1565-1575 11 p.Research output: Contribution to journal › Comment/debate
Open Access9 Scopus citations